covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Nuevos aspectos de tratamiento con yodo-131 en el cáncer diferenciado de tiroid...
Información de la revista
Vol. 48. Núm. 1.
Páginas 20-26 (enero 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 48. Núm. 1.
Páginas 20-26 (enero 2001)
Acceso a texto completo
Nuevos aspectos de tratamiento con yodo-131 en el cáncer diferenciado de tiroides
New aspects of iodine-131 treatment in patients with differentiated thyroid carcinoma
Visitas
5507
D. Fustera,**, I. Halperinb, S. Vidal-Sicarta, F. Lomeñaa
a Servicio de Medicina Nuclear
b Servicio de Endocrinología. Hospital Clínic. Barcelona
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

La medicina nuclear interviene en el manejo clínico de los pacientes con cáncer diferenciado de tiroides. El yodo-131 refleja el funcionalismo tiroideo y permite detectar la presencia de tejido tiroideo y de tumor residual tras la tiroidectomía total. La administración de dosis altas de yodo-131 destruye los restos tiroideos tumorales e identifica y permite tratar nuevas lesiones tumorales locales o a distancia. Recientemente han aparecido nuevas técnicas que han variado ostensiblemente los procedimientos de actuación en estos pacientes. Entre ellas destaca el estímulo de tejido tiroideo con hormona estimuladora del tiroides (TSH) recombinante con el fin de evitar los síntomas derivados del hipotiroidismo previo al yodo-131 o la administración de ácido retinoico como factor de rediferenciación tumoral. En algunos casos, pueden tener relevancia la determinación de tiroglobulina o los estudios con PET con el objetivo de mejorar la exactitud diagnóstica en estos pacientes.

En este trabajo se revisa la situación actual de la medicina nuclear en el diagnóstico, tratamiento y seguimiento evolutivo de este tipo de tumores.

Palabras clave:
Carcinoma diferenciado de tiroides
Yodo-131

Nuclear Medicine plays a role in the clinical management of patients with differentiated thyroid cancer. Iodine-131 reflects thyroid function and enables the detection of the presence of residual thyroid tissue and tumor, after complete thyroidectomy. The administration of high doses of Iodine- 131 destroys thyroid tumoral remnants and identifies and treats new local and distant tumoral lesions. Recently new techniques have appeared such as the stimulation of thyroid tissue with recombinant TSH as a means of obviating hypothyroidism prior to studies with Iodine-131, or the administration of retinoic acid as a possible factor of tumoral redifferentiation. Furthemore, thyroglobulin or PET studies are also relevant in some cases in the attempt to improve accuracy in the diagnosis of tumors. In this work, the current situation in Nuclear Medicine in the diagnosis, treatment and follow up of these tumors is reviewed.

Key words:
Differentiated thyroid cancer
Iodine-131
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Vilardell.
Pronóstico del cáncer de tiroides.
Med Clin (Barc), 2 (1997), pp. 62-64
[2.]
E.L. Mazzaferri.
Papillary thyroid carcinoma: Factors influencing prognosis and current therapy.
Semin Oncol, 14 (1987), pp. 315-332
[3.]
F. Grünwald, T. Kalicke, U. Feine, R. Lietzenmayer, K. Scheidhauer, M. Dietlein, et al.
Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre.
Eur J Nucl Med, 26 (1999), pp. 1547-1552
[4.]
A. Sanmartí, M. Foz.
Cáncer de tiroides.
Tratado de Medicina Clínica Medicine (Madrid), 35 (1989), pp. 1420-1427
[5.]
B. Cady, C.E. Sedgwick, W.A. Meissner, J.R. Bookwalter, V. Romagosa, J. Werber.
Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma.
Ann Surg, 88 (1964), pp. 610-618
[6.]
A. Waxman.
The significance of 131I scan dose in patients with thyroid cancer. Determination of ablation: Concise communication.
J Nucl Med, 22 (1988), pp. 861-865
[7.]
H.M. Park, O.W. Perkins, J.W. Edmondson, R.B. Schnute, A. Manatunga.
Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131.
Thyroid, 4 (1994), pp. 49-54
[8.]
H.M. Park, Y.H. Park, X.H. Zhou.
Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma.
Thyroid, 7 (1997), pp. 277-280
[9.]
J.C. Reynolds, J. Robbins.
The changing role of radioiodine in the management of differentiated thyroid cancer.
Semin Nucl Med, 27 (1997), pp. 152-164
[10.]
U.M. Varma.
Treatment of thyroid cancer: death rates after surgery and after surgery followed by sodium iodide 131I.
JAMA, 214 (1970), pp. 1437-1442
[11.]
E.E. Pochin.
Prospects from the treatment of thyroid carcinoma with radioiodine.
Clin Radiol, 18 (1967), pp. 113-135
[12.]
A.Z. Rudavsky, L.M. Freeman.
Treatment of scan negative, thyroglobulin positive metastatic thyroid cancer using radioiodine I-131 and recombinant human thyroid stimulating hormone.
J Clin Endocrinol Metab, 82 (1997), pp. 11-14
[13.]
J.R. Hurley, D.V. Becker.
The use of radioiodine in the management of thyroid cancer.
Nucl Med Ann, (1983), pp. 329-384
[14.]
C.C. Kuni, W.C. Klingensmith.
Failure of low doses of 131I to ablate resi-dual thyroid tissue following surgery for thyroid cancer.
Radiology, 137 (1980), pp. 773-774
[15.]
A.R. Siddiqui, J. Edmondson, H.N. Wellman, R.C. Hamaker, R.E. Lingeman, H.M. Park, et al.
Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma.
Clin Nucl Med, 6 (1981), pp. 158-161
[16.]
C. Ramacciotti, H.T. Pretorius, B.R. Line, J.M. Goldman, J. Robbins.
Ablation of non malignant thyroid remnants with low doses of radioactive iodine: Concise communication.
J Nucl Med, 23 (1982), pp. 483-489
[17.]
W.H. Beierwaltes.
An analysis of ablation of thyroid remnants with 131I in 511 patients from 1947-1984 Experience at University of Michigan.
J Nucl Med, 25 (1984), pp. 1287-1293
[18.]
W.H. Beierwaltes.
The treatment of thyroid carcinoma with radioactive iodine.
Semin Nucl Med, 25 (1984), pp. 1287-1293
[19.]
E.G. Movius, J. Robbins, L.R. Pierce.
The value of lithium in radioiodine therapy of thyroid carcinoma.
Frontiers in thyroidology,
[20.]
F. Pons, I. Carrió, M. Estorch, M. Ginajume, J. Pons, R. Milian.
Lithium as an adjuvant of Iodine-131 when treating patients with well-differentiated thyroid carcinoma.
Clin Nucl Med, 12 (1987), pp. 644-647
[21.]
R.D. Leeper, K. Shimaoka.
Treatment of metastatic thyroid cancer.
Clin Endocrinol Metab, 9 (1980), pp. 383-404
[22.]
A.W. Golden, J.B. Davey.
The ablation of normal thyroid tissue with iodine-131.
Br J Radiol, 36 (1963), pp. 340-345
[23.]
D. Van Nostrand, J. Neutze, F. Atkins.
Side-effects of rational dose 131I therapy for metastatic well differentiated thyroid carcinoma.
J Nucl Med, 27 (1986), pp. 1519-1527
[24.]
C.J. Edmonds.
Treatment of thyroid cancer.
Clin Endocrinol Metab, 8 (1979), pp. 223-243
[25.]
R.S. Benua, N.R. Cicale, M. Sonenberg, R.W. Rawson.
The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer.
Am J Roentgenol, 87 (1962), pp. 171-182
[26.]
F. De Vathaire, M. Schlumberger, M.J. Delisle, C. Francese, C. Challeton, E De la Genardiere, et al.
Leukemias and cancers following 131 I administration for thyroid cancer.
Br J Cancer, 75 (1997), pp. 734-739
[27.]
M. Schlumberger, C. Challeton, F. De Vathaire, J.P. Travagli, P. Gardet, J.D. Lumbroso, et al.
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
J Nucl Med, 37 (1996), pp. 598-605
[28.]
C.A. Spencer, C.C. Wang.
Thyroglobulin measurement. Techniques, clinical benefits and pitfalls.
Endocrinol Metab Clin North Am, 24 (1995), pp. 841-863
[29.]
A. Kumar, D.H. Shah, U. Shrihari, S.R. Dandekar, U. Vijayan, S.M. Sharma.
Significance of antithyroglobulin autoantibodies in differtentiated thyroid carcinoma.
Thyroid, 4 (1994), pp. 199-202
[30.]
F. Grunwald, E. Pakos, H. Bender, C. Menzel, R. Otte, H. Palmedo, et al.
Redifferentiation therapy with retinoic acid in follicular thyroid cancer.
J Nucl Med, 39 (1998), pp. 1555-1558
[31.]
C. Koerber, C. Schmutzler, J. Rendl, J. Koehrle, H. Griesser, D. Simon, et al.
Increased uptake in local recurrence and distant metastases after second treatment with retinoic acid.
Clin Nucl Med, 24 (1999), pp. 849-851
[32.]
K.M. Van Tol, J.M. Hew, P.L. Jager, A. Vermey, R.P.F. Dullaart, T.P. Links.
Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma.
Clin Endocrinol (Oxf), 52 (2000), pp. 653-659
[33.]
M. Schlumberger, F. Pacini.
Thyroid tumors.
[34.]
C.H. Kirkpatrick, J.C. Meek, R.R. Rich.
Mechanism of allergy to components of commercial bovine thyrotropin.
J Allergy Clin Immunol, 51 (1973), pp. 296-302
[35.]
W.B. Sherman, S.C. Werner.
Generalized allergic reaction to bovine thyrotropin.
JAMA, 190 (1964), pp. 244-245
[36.]
S.G. Park, J.C. Reynolds, F. Brucker-Davis, M. Whatley, K. McEllin, D. Maxted.
Iodine kinetics during I-131 scanning in patients with thyroid cancer: comparison of studies with recombinant human TSH (rhTSH) vs. hypothyroidism.
J Nucl Med, 37 (1996), pp. 15P
[37.]
P.W. Ladenson, L.E. Braverman, E.L. Mazzaferri, F. Brucker-Davis, D.S. Cooper, J.R. Garber, et al.
Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radiactive iodine scanning in patients with thyroid carcinoma.
N Engl J Med, 337 (1997), pp. 888-896
[38.]
J.R. Rodríguez.
La TSH humana recombinante (rhTSH) en el control y seguimiento de los pacientes con cáncer diferenciado de tiroides: más cerca del objetivo.
Rev Esp Med Nucl, 18 (1999), pp. 401-407
[39.]
H. Uematsu, N. Sadato, T. Ohtsubo, T. Tsuchida, S. Nakamura, K. Sugimoto, et al.
Fluorine-18-fluoro doxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
J Nucl Med, 39 (1998), pp. 453-459
[40.]
F. Grunwald, C. Menzel, H. Bender, H. Pamedo, P. Willkomm, J. Ruhlmann, et al.
Comparison of 18FDG-PET with 131-Iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer.
Thyroid, 7 (1997), pp. 327-335
[41.]
H. Jadvar, I.R. McDougall, G.M. Segall.
Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography.
Nucl Med Commun, 19 (1998), pp. 547-554
[42.]
M. Sasaki, Y. Ichiya, y. Kuwabara, Y. Akashi, T. Yoshida, T. Fukumura, et al.
An evaluation of FDG-PET in the detection and differentiation of thyroid tumours.
Nucl Med Commun, 18 (1997), pp. 957-963
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos